Easton Pharmaceuticals Inc
OTC:EAPH
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Easton Pharmaceuticals Inc
Additional Paid In Capital
Easton Pharmaceuticals Inc
Additional Paid In Capital Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Additional Paid In Capital | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Easton Pharmaceuticals Inc
OTC:EAPH
|
Additional Paid In Capital
$46.6m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Bausch Health Companies Inc
TSX:BHC
|
Additional Paid In Capital
$357m
|
CAGR 3-Years
31%
|
CAGR 5-Years
-5%
|
CAGR 10-Years
2%
|
|
|
Canopy Growth Corp
TSX:WEED
|
Additional Paid In Capital
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Cronos Group Inc
TSX:CRON
|
Additional Paid In Capital
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Mind Medicine (MindMed) Inc
NASDAQ:MNMD
|
Additional Paid In Capital
$661.8m
|
CAGR 3-Years
25%
|
CAGR 5-Years
216%
|
CAGR 10-Years
N/A
|
|
|
K
|
Knight Therapeutics Inc
TSX:GUD
|
Additional Paid In Capital
CA$32.4m
|
CAGR 3-Years
11%
|
CAGR 5-Years
12%
|
CAGR 10-Years
17%
|
|
Easton Pharmaceuticals Inc
Glance View
Easton Pharmaceuticals, Inc. engages in the design, development, and marketing of drugs, therapeutic, and cosmetic healthcare products. The company is headquartered in North York, Ontario. The company went IPO on 2000-09-29. The firm has a transdermal delivery technology (Viorra Delivery Matrix or VDM), which is incorporated in a line of therapeutic over-the-counter (OTC) products. The firm owns topically-delivered drugs and therapeutic/cosmetic healthcare products focused on cancer and other health problems geared towards female sexual dysfunction, wound healing, pain, motion sickness and other conditions. The firm's products are in various stages of commercialization. The firm's products include Nauseasol, which is a motion sickness gel; Skin Renou HA, which is an anti-aging wrinkle cream; Kenestrin Gel, which is a is a pain relief gel; Viorra, which serves as an aid to the relief of female sexual arousal disorder (FSAD); XILIVE, which is an early-stage cancer drug, and FSAD) drug, which includes a water-based complex polymer matrix.
See Also
What is Easton Pharmaceuticals Inc's Additional Paid In Capital?
Additional Paid In Capital
46.6m
USD
Based on the financial report for Dec 31, 2020, Easton Pharmaceuticals Inc's Additional Paid In Capital amounts to 46.6m USD.
What is Easton Pharmaceuticals Inc's Additional Paid In Capital growth rate?
Additional Paid In Capital CAGR 1Y
0%
Over the last year, the Additional Paid In Capital growth was 0%.
